Updated:
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the...
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
General information
Firm type
Asset Manager
Year founded
2012
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Brian Lian
CEO
Sector focus
Frequently asked questions
Who runs key development and investment decisions at Viking Therapeutics?
Brian Lian, Ph.D., has served as President and CEO since the company’s founding in 2012. The board of directors and executive leadership team make capital-allocation and pipeline-prioritization decisions within the standard public-company governance framework.
How is Viking Therapeutics’ obesity program positioned against Eli Lilly and Novo Nordisk?
Viking’s lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist available in both subcutaneous and oral formulations. The Phase 3 program for the oral version, initiated in January 2025, aims to demonstrate competitive weight-loss efficacy and tolerability in the same incretin market that Lilly’s tirzepatide and Novo’s semaglutide now dominate.
What therapeutic areas does Viking Therapeutics avoid?
Viking has not disclosed any pipeline activity outside metabolic and endocrine disorders. Its public pipeline is concentrated on NASH, X-ALD, and obesity, and the company has not announced oncology, neurology, or anti-inflammatory programs.
Is Viking Therapeutics structured as a family office or venture firm?
Viking is a clinical-stage, publicly traded biopharmaceutical company listed on Nasdaq. It is not a family office, and it does not manage third-party capital or invest in external funds.
How does Viking Therapeutics fund its operations?
The company finances its operations primarily through follow-on public equity offerings and at-the-market (ATM) programs. It does not operate an in-house discretionary investment portfolio or deploy capital as a multi-strategy asset manager.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: